Moonmoon Kazi/LinkedIn
Jun 15, 2026, 12:46
Moonmoon Kazi: Climb Bio Presents Phase 1b ITP Trial Data at EHA 2026
Moonmoon Kazi, Sr. Medical Director at Climb Bio, shared a post on LinkedIn:
“It has been six months into my role at Climb Bio and I’m so grateful to be part of an organization with a clear, science‑driven vision for building a focused and differentiated pipeline.
Presenting preliminary data from our Phase 1b ITP trial was a meaningful milestone, reinforcing how thoughtful translational strategy and rigorous early clinical execution inform downstream pipeline decisions.
I’m energized by the clarity of purpose and the caliber of the team, and I look forward to helping advance programs with the potential to meaningfully impact patients.”
Stay updated with Hemostasis Today.
-
Jun 15, 2026, 12:44Wolfgang Miesbach: Base Editing and the Future of Sickle Cell Disease Therapy
-
Jun 15, 2026, 12:31Chandrashekhar Athare: EHA 2026 Concludes with Lasting Impact and New Collaborations
-
Jun 15, 2026, 10:49Aurelio Maggio: How Is The Treatment Landscape Of Thrombotic Thrombocytopenic Purpura Evolving?
-
Jun 15, 2026, 10:49Marek Mráz: A Landmark EHA 2026 for Our Lab
-
Jun 15, 2026, 10:32Magnus Ek: Operational Excellence in Delivering Seamless Access for 17,000 Delegates at EHA 2026 Congress
-
Jun 15, 2026, 10:15Carol Bewick: Why the Global Community Makes EHA 2026 Unforgettable
-
Jun 15, 2026, 10:07Habib Bennaceur: Driving Haemoglobinopathies Progress Across Multiple Clinical Programmes At EHA 2026
-
Jun 14, 2026, 22:49Cihan Ay: From First Oral Presentation to Pro and Con Debate – A 20-Year EHA Journey
-
Jun 14, 2026, 19:54Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?